scholarly journals Long-term outcome and predictors of long-term disease activity in natalizumab-treated patients with multiple sclerosis: real life data from the Austrian MS Treatment Registry

2021 ◽  
Author(s):  
Michael Guger ◽  
◽  
Christian Enzinger ◽  
Fritz Leutmezer ◽  
Franziska Di Pauli ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Disease Activity ◽  
Rate Ratio ◽  
Disease Duration ◽  
Treatment Initiation ◽  
Incidence Rate Ratio ◽  
Real Life ◽  
Life Data ◽  
Real Life Data

Abstract Objectives To evaluate long-term effectiveness of natalizumab (NTZ) and to determine demographic, clinical, and radiological predictors regarding long-term disease activity (≥ 7 years) in a nationwide observational cohort, using data collected prospectively in a real-life setting. Materials and methods We analysed data from 230 patients from the Austrian Multiple Sclerosis Treatment Registry (AMSTR), who had started treatment with NTZ at any time since 2006 and stayed on NTZ for at least 7 years without treatment gap of more than three months. Results Estimated mean annualised relapse rates (ARR) over a mean treatment period of 9.3 years were 0.07 for NTZ. Sustained EDSS progression for 12 weeks was observed in 36 (19%) patients and for 24 weeks in 31 (16.3%) cases. Sustained EDSS regression for 12 and 24 weeks was seen in 45 (23.7%) and 42 (22.1%) cases. The baseline parameters ≥ 1 Gadolinium-enhancing MRI lesion(s) [incidence rate ratio (IRR) of 0.409 (95% CI 0.283–0.593), p = 0.001], ARR ≤ 1 in the prior 12 month before treatment initiation with NTZ [IRR of 0.353 (95% CI 0.200–0.623), p = 0.001] and EDSS ≤ 1 [incidence rate ratio (IRR) of 0.081 (95% CI 0.011–0.581), p = 0.012] were significantly associated with a reduced relapse risk, whereas a disease duration ≤ 5 years increased significantly the ARR [IRR of 1.851 (95% CI 1.249–2.743), p = 0.002]. The only predictive baseline parameter for experiencing EDSS progression (sustained for 12 and 24 weeks) was age > 35 years [HR of 2.482 (95% CI 1.110–5.549), p = 0.027, and HR of 2.492 (95% CI 1.039–5.978), p = 0.041, respectively]. Conclusions These real-life data show a stable disease course regarding relapse activity and disease progression under NTZ treatment for more than 7 years. The main predictors for disease activity were higher relapse rate before treatment initiation, higher disability, shorter disease duration and absence of Gadolinium-enhancing MRI lesions at baseline. Older age at NTZ start was the only significant risk factor for disease progression over long-term.

scholarly journals Association of clinical epidemiological factors to polypharmacy among patients with multiple sclerosis: real-life data

2021 ◽  
Vol 46 ◽  
pp. e021212
Author(s):  
Vanessa Marcon de Oliveira ◽  
Cinthia Caldas Rios ◽  
Vanessa Terezinha Gubert ◽  
Cristiane Munaretto Ferreira ◽  
Erica Freire de Vasconcelos-Pereira ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Relapse Prevention ◽  
Disease Duration ◽  
Real Life ◽  
Disease Modifying Drugs ◽  
Epidemiological Factors ◽  
Real Life Data ◽  
Multiple Sclerosis Patients ◽  
A Prospective Study

Introduction: Treatment for multiple sclerosis should focus on relapse prevention and treatment, as well as symptom and disease progression control, which require the use of multiple medications. Objective: To evaluate the association of polypharmacy and related clinical, epidemiological factors in multiple sclerosis patient cohorts. Methods: It was conducted a prospective study of multiple sclerosis patients that held a prescription of disease-modifying drugs between January and December 2017. The medications were analyzed and classified as either long-term or as-needed medications for therapeutic objective and prescription status purposes. Results: During 2017, 124 patients were attended, 106 were eligible for the study, and 81 agreed to participate. The average age was 40.95±11.69 years. The disease duration varied between 6 months and 30 years, with a median of 7 years. More than half of the multiple sclerosis patients suffered from comorbidities (54.32%), and 76.54% were categorized as polypharmacy. The comparison of polypharmacy between the groups yielded significant differences for comorbidities and employment status and regarding age between patients with polypharmacy and patients without polypharmacy of long-term medications. Conclusion: The age of the patient and the presence of comorbidities are important factors related to polypharmacy.

121 LONG-TERM EFFICACY AND SAFETY OF TRANS - URETHRAL NEEDLE ABLATION (TUNA ®) IN OVER 500 MEN WITH LUTS/BPH: THE EAU REAL-LIFE DATA REGISTRY

2011 ◽  
Vol 10 (2) ◽  
pp. 63
Author(s):  
A. Tubaro ◽  
K. Höfner ◽  
H. Villavicencio ◽  
La Rosette J.J. De ◽  
C.R. Chapple
Keyword(s):  
Real Life ◽  
Efficacy And Safety ◽  
Life Data ◽  
Term Efficacy ◽  
Data Registry ◽  
Real Life Data

AB0537 Superior low disease activity and remission rates when rituximab is initiated after the first anti-TNF failure: Real life data

2013 ◽  
Vol 71 (Suppl 3) ◽  
pp. 669.2-669
Author(s):  
I. Ancuta ◽  
C. Codreanu ◽  
R. Ionescu ◽  
M. Parvu ◽  
M. Bojinca
Keyword(s):  
Disease Activity ◽  
Real Life ◽  
Low Disease Activity ◽  
Life Data ◽  
Real Life Data ◽  
Remission Rates

scholarly journals Correction to: Switching from natalizumab to fingolimod treatment in multiple sclerosis: real life data from the Austrian MS Treatment Registry

2019 ◽  
Vol 266 (11) ◽  
pp. 2678-2678
Author(s):  
Michael Guger ◽  
◽  
Christian Enzinger ◽  
Fritz Leutmezer ◽  
Jörg Kraus ◽  
...  
Keyword(s):  
Multiple Sclerosis ◽  
Real Life ◽  
Life Data ◽  
Real Life Data

scholarly journals Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaboration

RMD Open ◽  
2020 ◽  
Vol 6 (3) ◽  
pp. e001280
Author(s):  
Brigitte Michelsen ◽  
Ulf Lindström ◽  
Catalin Codreanu ◽  
Adrian Ciurea ◽  
Jakub Zavada ◽  
...  
Keyword(s):  
Ankylosing Spondylitis ◽  
Disease Activity ◽  
Axial Spondyloarthritis ◽  
Real Life ◽  
Routine Care ◽  
Retention Rates ◽  
Inactive Disease ◽  
Life Data ◽  
Real Life Data ◽  
Time Since Diagnosis

ObjectivesTo explore 6-month and 12-month secukinumab effectiveness in patients with axial spondyloarthritis (axSpA) overall, as well as across (1) number of previous biologic/targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs), (2) time since diagnosis and (3) different European registries.MethodsReal-life data from 13 European registries participating in the European Spondyloarthritis Research Collaboration Network were pooled. Kaplan-Meier with log-rank test, Cox regression, χ² and logistic regression analyses were performed to assess 6-month and 12-month secukinumab retention, inactive disease/low-disease-activity states (Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <2/<4, Ankylosing Spondylitis Disease Activity Score (ASDAS) <1.3/<2.1) and response rates (BASDAI50, Assessment of Spondyloarthritis International Society (ASAS) 20/40, ASDAS clinically important improvement (ASDAS-CII) and ASDAS major improvement (ASDAS-MI)).ResultsWe included 1860 patients initiating secukinumab as part of routine care. Overall 6-month/12-month secukinumab retention rates were 82%/72%, with significant (p<0.001) differences between the registries (6-month: 70–93%, 12-month: 53–86%) and across number of previous b/tsDMARDs (b/tsDMARD-naïve: 90%/73%, 1 prior b/tsDMARD: 83%/73%, ≥2 prior b/tsDMARDs: 78%/66%). Overall 6-month/12-month BASDAI<4 were observed in 51%/51%, ASDAS<1.3 in 9%/11%, BASDAI50 in 53%/47%, ASAS40 in 28%/22%, ASDAS-CII in 49%/46% and ASDAS-MI in 25%/26% of the patients. All rates differed significantly across number of previous b/tsDMARDs, were numerically higher for b/tsDMARD-naïve patients and varied significantly across registries. Overall, time since diagnosis was not associated with secukinumab effectiveness.ConclusionsIn this study of 1860 patients from 13 European countries, we present the first comprehensive real-life data on effectiveness of secukinumab in patients with axSpA. Overall, secukinumab retention rates after 6 and 12 months of treatment were high. Secukinumab effectiveness was consistently better for bionaïve patients, independent of time since diagnosis and differed across the European countries.

scholarly journals Long-Term (7 Years) Experience of Nintedanib in IPF Patients in Crete: A Real Life Data Study

2020 ◽  
Author(s):  
K. Antoniou ◽  
E. Tsitoura ◽  
A. Trachalaki ◽  
E. Vasarmidi ◽  
G. Margaritopoulos ◽  
...  
Keyword(s):  
Real Life ◽  
Life Data ◽  
Real Life Data
Sign in / Sign up

Export Citation Format

Share Document